Filing Flows › Health Care › CapsoVision (CV)
CapsoVision (CV) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · CapsoVision (CV) Q2 2026 earnings results →
Q2 2026 Revenue up 10% year over year to $3.6M · 205¢ of every $1 of revenue lost · operating margin -208.1%
CapsoVision made $3.6M in Q2 2026 (+10% Y/Y). Operating margin -208.1%, net loss $7.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $3.6M in Q2 2026, up 10% year over year and up 30% from the previous quarter.
Gross margin was 51.4%, down 3.3 points from Q2 2025. Operating costs exceeded revenue by $7.6M, an operating margin of -208.1%. Operating expenses grew 46% against revenue growth of 10%. The fastest-growing cost line was General & admin (+80%). The quarter ended with a net loss of $7.5M, wider than the previous quarter's $7.0M loss.
Operating cash flow was −$8.4M. Non-cash charges added back $58K of depreciation and amortization and $577K of share-based compensation. Working capital and other items used $1.6M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $3.6M | +10% | -208.1% | −$7.5M | −$8.4M |
| Q1 2026 | 10-Q | May 14, 2026 | $2.8M | +0.3% | -254.0% | −$7.0M | −$6.1M |
| Q4 2025 | 10-K | Mar 26, 2026 | $3.9M | +14% | -190.5% | −$7.4M | −$7.7M |
| Q3 2025 | 10-Q | Nov 13, 2025 | $3.5M | +19% | -226.7% | −$7.9M | −$5.7M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $3.3M | +17% | -140.3% | −$4.6M | −$4.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About CapsoVision
We are a global commercial-stage medical technology company focused on creating diagnostic and screening products to identify abnormalities of the GI tract. We develop advanced imaging and AI technologies in creating such products while maximizing the flexibility, convenience, profitability, and safety of patient care. We are a Delaware company, incorporated in 2005. Our corporate headquarters is located in Saratoga, California. Currently, our GI-tract capsule endoscopy solution comprises our single-use CapsoCam capsule and the associated software, CapsoCloud and CapsoView.
In its own words, from its 10-K, filed Mar 26, 2026.
CapsoVision against its Electromedical & Electrotherapeutic Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +10% against the peers' median +14%. Operating margin: -208.1% against the peers' median 6.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CV CapsoVision | Q2 2026 | $3.6M | +10% | -208.1% |
| MDT Medtronic | Q1 FY27 | $9.8B | +14% | 18.1% |
| ITGR Integer Holdings | Q3 2026 | $450M | -4% | 6.3% |
| LIVN LivaNova | Q3 2026 | $393M | +10% | 7.2% |
| CNMD Conmed | Q3 2026 | $336M | -0.7% | 11.1% |
| TMDX TransMedics Group | Q3 2026 | $203M | +41% | 13.9% |
| AXGN Axogen | Q3 2026 | $75.8M | +26% | 1.3% |
| OM Outset Medical | Q3 2026 | $33.6M | +14% | -36.5% |
| CBLL Ceribell | Q3 2026 | $29.3M | +30% | -70.0% |
Source: CapsoVision 10-Q on SEC EDGAR · CIK 1378325 · Electromedical & Electrotherapeutic Apparatus
13F: who owns CV and who is buying
More on CV
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results